Skip to main content

WaferGen Gets $2M Loan

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems has entered into a $2 million loan agreement with Oxford Finance Corp., the Fremont, Calif.-based firm disclosed in a filing with the US Securities and Exchange Commission today.

The agreement was effective Dec. 7, pursuant to a secured promissory note. The note will accrue at a fixed rate of roughly 13 percent.

In connection with the loan, WaferGen issued to Oxford a warrant to purchase 95,368 of the firm's common stock. The warrant is exercisable immediately at a price of $1.468 per share and expires in five years.

WaferGen's stock closed at $1.27 in Monday trade on the OTC Bulletin Board.

The firm said that it intends to use the loan for general corporate purposes.

Last month, WaferGen reported third-quarter revenues of $633,000, as a result of the summer launch of its SmartChip Real-Time PCR System. The firm finished its quarter ended Sept. 30, with $4.4 million in cash and cash equivalents.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.